Medicare coverage restrictions prevent early Alzheimer's detection, worsening outcomes for millions
Source: "Medicare coverage gaps block early Alzheimer's detection for millions | Fox News." May 21, 2026. www.foxnews.com
The Gist
Millions of Americans can't get early Alzheimer's testing because Medicare won't pay for it until they're already showing symptoms. By then, it's often too late for the best treatments to work effectively.
Conclusion
Congress should pass legislation requiring Medicare to cover early detection blood tests and streamline coverage for FDA-approved Alzheimer's therapies
Premises
- 7.2 million Americans have Alzheimer's, affecting 25-50 million people when including family and caregivers
- Early detection blood tests can identify Alzheimer's markers before symptoms appear, enabling earlier intervention
- Medicare only covers blood tests after symptoms develop, not for early detection screening
- Early treatment can delay symptom progression, extending quality of life and delaying need for institutional care
- Medicare's registry requirements for infusion treatments create barriers, especially in rural areas
- Without intervention, Alzheimer's cases could nearly double to 13.8 million by 2060
Assumptions
- Early detection and treatment of Alzheimer's leads to better outcomes than late-stage intervention
- Medicare coverage policies significantly influence patient access to medical care
- Congressional action can effectively reform Medicare coverage policies
- The financial and human costs of delayed treatment outweigh the costs of expanded coverage
- Current scientific understanding of Alzheimer's biomarkers is sufficient to justify screening programs